Processa Pharmaceuticals, Inc. (PCSA) shareholders
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.86+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $5.20MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
9.1%
0M of 3M shares
Institutional holders
12
4 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
45 buys · 0 sales
Net bought $224.96K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chiliz Group Ltd. | 5,467,181 | 10.90% | 13D (active) amendment | Aug 5, 2025 |
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%) | 3,018,238 | 9.99% | 13G (passive) | Jun 17, 2025 |
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 2,663,078 | 9.90% | 13G (passive) | Jun 17, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 578,605 | 9.99% | 13G (passive) | Mar 31, 2025 |
| HX Entertainment Ltd | 305,644 | 13.00% | 13D (active) amendment | Feb 13, 2026 |
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (7.00%) | 200,000 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (8.10%), Daniel B. Asher (8.10%) | 200,000 | 8.10% | 13G (passive) amendment | Dec 31, 2025 |
| Guy Levy Joint filing with Soleus Capital Master Fund, L.P. (5.80%), Soleus Capital, LLC (5.80%) and 3 more | 160,943 | 5.80% | 13G (passive) | Aug 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PCSA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Connective Capital Management, LLC | 85,274 | 3.05% | $163.73K | +14,538 | 0.12% |
| Stonepine Capital Management, LLC | 55,000 | 1.97% | $105.60K | – | 0.06% |
| Geode Capital Management, LLC | 22,090 | 0.79% | $42.41K | −2,818 | 0.00% |
| Citadel Advisors LLC | 21,306 | 0.76% | $40.91K | New | 0.00% |
| XTX Topco Ltd | 13,292 | 0.48% | $25.52K | New | 0.00% |
| Jane Street Group, LLC | 13,264 | 0.47% | $25.47K | New | 0.00% |
| Vanguard Capital Management LLC | 12,729 | 0.46% | $24.44K | – | 0.00% |
| StoneX Group Inc. | 11,437 | 0.41% | $29.62K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 10,857 | 0.39% | $20.85K | – | 0.00% |
| UBS Group AG | 7,794 | 0.28% | $14.96K | +5,263 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,499 | 0.09% | $4.80K | +1,581 | 0.00% |
| Jones Financial Companies Lllp | 7 | 0.00% | $13 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 12 | 0M | 9.1% | 4 / 3 | 1 / 2 | 0M | 0M |
| Q1 2026 | 10 | 0M | 6.4% | 4 / 2 | 2 / 3 | 0M | 0M |
| Q4 2025 | 10 | 0M | 4.1% | 3 / 4 | 2 / 7 | 0M | 0M |
| Q3 2025 | 14 | 0M | 2.6% | 7 / 3 | 2 / 6 | 0M | 0M |
| Q2 2025 | 13 | 0M | 0.5% | 6 / 4 | 1 / 2 | 0M | 0M |
| Q1 2025 | 9 | 0M | 0.2% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q4 2024 | 8 | 0M | 0.1% | 2 / 2 | 1 / 2 | 0M | 0M |
| Q3 2024 | 8 | 0M | 0.1% | 1 / 2 | 0 / 2 | 0M | 0M |
| Q2 2024 | 9 | 0M | 0.1% | 1 / 0 | 3 / 3 | 0M | 0M |
| Q1 2024 | 11 | 0M | 0.2% | 11 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held PCSA in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PCSA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 14,221 | 0.51% | $36.41K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 12,729 | 0.46% | $24.44K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 2,088 | 0.07% | $5.35K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 969 | 0.03% | $2.48K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| George K. Ng | Chief Executive Officer, Director | 21,380 | 0.77% | Aug 11, 2026 |
| David Young | Pres. Research & Development, Director | 24,412 | 0.87% | Jul 1, 2026 |
| Russell Skibsted | Chief Financial Officer | 16,689 | 0.60% | Jul 28, 2026 |
| Patrick Lin | Chief Business - Strategy Off | 14,853 | 0.53% | Jul 28, 2026 |
| Wendy Guy | Chief Administrative Officer | 14,727 | 0.53% | Jul 28, 2026 |
| Sian Bigora | Chief Development Officer | 7,748 | 0.28% | May 19, 2026 |
| Sheila Gujrathi | Director | – | – | Jul 30, 2026 |
| Geraldine Pannu | Director | 2,391 | 0.09% | Jul 28, 2026 |
| James R. Neal | Director | 1,021 | 0.04% | Jul 28, 2026 |
| Justin W. Yorke | Director | 2,099 | 0.08% | Jul 28, 2026 |
| Khoso Baluch | Director | 2,528 | 0.09% | Jul 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George K. Ng Chief Executive Officer, Director | Aug 8, 2026 | Option exercise | +1,600 | – | – | 17,092 |
| George K. Ng Chief Executive Officer, Director | Jul 1, 2026 | Buy | +3,057 | $1.93 | $5.90K | 15,492 |
| Wendy Guy Chief Administrative Officer | Jun 30, 2026 | Buy | +2,436 | $1.93 | $4.70K | 14,394 |
| Russell Skibsted Chief Financial Officer | Jun 30, 2026 | Buy | +3,277 | $1.93 | $6.32K | 16,689 |
| Patrick Lin Chief Business - Strategy Off | Jun 30, 2026 | Buy | +2,106 | $1.93 | $4.06K | 13,113 |
| David Young Pres. Research & Development, Director | Jun 30, 2026 | Buy | +2,531 | $1.93 | $4.88K | 21,729 |
| Khoso Baluch Director | Jun 26, 2026 | Option exercise | +203 | – | – | 2,528 |
| Geraldine Pannu Director | Jun 26, 2026 | Option exercise | +203 | – | – | 2,391 |
| James R. Neal Director | Jun 26, 2026 | Option exercise | +203 | – | – | 1,021 |
| Justin W. Yorke Director | Jun 26, 2026 | Option exercise | +203 | – | – | 353 |
| Russell Skibsted Chief Financial Officer | Jun 15, 2026 | Buy | +2,654 | $2.22 | $5.89K | 13,412 |
| George K. Ng Chief Executive Officer, Director | Jun 15, 2026 | Buy | +2,465 | $2.22 | $5.47K | 12,435 |
| Wendy Guy Chief Administrative Officer | Jun 15, 2026 | Buy | +2,118 | $2.22 | $4.70K | 11,958 |
| Patrick Lin Chief Business - Strategy Off | Jun 15, 2026 | Buy | +1,831 | $2.22 | $4.06K | 11,007 |
| David Young Pres. Research & Development, Director | Jun 15, 2026 | Buy | +2,067 | $2.22 | $4.59K | 19,198 |
| Patrick Lin Chief Business - Strategy Off | May 29, 2026 | Buy | +1,582 | $2.57 | $4.07K | 9,176 |
| George K. Ng Chief Executive Officer, Director | May 29, 2026 | Buy | +2,129 | $2.57 | $5.47K | 9,970 |
| David Young Pres. Research & Development, Director | May 29, 2026 | Buy | +1,786 | $2.57 | $4.59K | 17,131 |
| Wendy Guy Chief Administrative Officer | May 29, 2026 | Buy | +1,829 | $2.57 | $4.70K | 9,840 |
| Russell Skibsted Chief Financial Officer | May 29, 2026 | Buy | +2,292 | $2.57 | $5.89K | 10,758 |
| Russell Skibsted Chief Financial Officer | May 15, 2026 | Buy | +1,984 | $2.97 | $5.89K | 8,466 |
| Wendy Guy Chief Administrative Officer | May 15, 2026 | Buy | +1,583 | $2.97 | $4.70K | 8,011 |
| George K. Ng Chief Executive Officer, Director | May 15, 2026 | Buy | +1,843 | $2.97 | $5.47K | 7,841 |
| Patrick Lin Chief Business - Strategy Off | May 15, 2026 | Buy | +1,369 | $2.97 | $4.07K | 7,594 |
| David Young Pres. Research & Development, Director | May 15, 2026 | Buy | +1,545 | $2.97 | $4.59K | 15,345 |
| Sian Bigora Chief Development Officer | Apr 30, 2026 | Buy | +1,971 | $2.71 | $5.34K | 7,481 |
| David Young Pres. Research & Development, Director | Apr 30, 2026 | Buy | +1,706 | $2.69 | $4.59K | 13,813 |
| Sian Bigora Chief Development Officer | Apr 30, 2026 | Buy | +1,986 | $2.69 | $5.34K | 7,496 |
| Patrick Lin Chief Business - Strategy Off | Apr 30, 2026 | Buy | +1,511 | $2.69 | $4.06K | 6,236 |
| George K. Ng Chief Executive Officer, Director | Apr 30, 2026 | Buy | +2,034 | $2.69 | $5.47K | 6,013 |
| Russell Skibsted Chief Financial Officer | Apr 30, 2026 | Buy | +2,190 | $2.69 | $5.89K | 6,498 |
| Wendy Guy Chief Administrative Officer | Apr 30, 2026 | Buy | +1,748 | $2.69 | $4.70K | 6,441 |
| George K. Ng Chief Executive Officer, Director | Apr 15, 2026 | Buy | +1,843 | $2.97 | $5.47K | 3,979 |
| George K. Ng Chief Executive Officer, Director | Apr 15, 2026 | Buy | +1,843 | $2.97 | $5.47K | 3,979 |
| George K. Ng Chief Executive Officer, Director | Apr 15, 2026 | Buy | +1,843 | $2.97 | $5.47K | 5,492 |
| Patrick Lin Chief Business - Strategy Off | Apr 15, 2026 | Buy | +1,369 | $2.97 | $4.07K | 4,725 |
| Russell Skibsted Chief Financial Officer | Apr 15, 2026 | Buy | +1,984 | $2.97 | $5.89K | 4,308 |
| Wendy Guy Chief Administrative Officer | Apr 15, 2026 | Buy | +1,583 | $2.97 | $4.70K | 4,693 |
| David Young Pres. Research & Development, Director | Apr 15, 2026 | Buy | +1,545 | $2.97 | $4.59K | 12,107 |
| Sian Bigora Chief Development Officer | Apr 15, 2026 | Buy | +1,799 | $2.97 | $5.34K | 5,510 |
| George K. Ng Chief Executive Officer, Director | Mar 31, 2026 | Buy | +2,136 | $2.54 | $5.43K | 2,136 |
| James R. Neal Director | Mar 31, 2026 | Buy | +789 | $2.54 | $2.00K | 818 |
| Sian Bigora Chief Development Officer | Mar 31, 2026 | Buy | +2,107 | $2.54 | $5.35K | 3,711 |
| Patrick Lin Chief Business - Strategy Off | Mar 31, 2026 | Buy | +1,603 | $2.54 | $4.07K | 3,356 |
| Khoso Baluch Director | Mar 31, 2026 | Buy | +2,269 | $2.54 | $5.76K | 2,325 |
| Wendy Guy Chief Administrative Officer | Mar 31, 2026 | Buy | +1,854 | $2.54 | $4.71K | 3,110 |
| Russell Skibsted Chief Financial Officer | Mar 31, 2026 | Buy | +2,324 | $2.54 | $5.90K | 2,324 |
| George K. Ng Chief Executive Officer, Director | Mar 31, 2026 | Buy | +2,136 | $2.54 | $5.43K | 3,649 |
| David Young Pres. Research & Development, Director | Mar 31, 2026 | Buy | +1,810 | $2.54 | $4.60K | 10,562 |
| Geraldine Pannu Director | Mar 31, 2026 | Buy | +2,072 | $2.54 | $5.26K | 2,188 |
| Wendy Guy Chief Administrative Officer | Jan 1, 2026 | Option exercise | +193 | – | – | 1,256 |
| David Young Pres. Research & Development, Director | Jan 1, 2026 | Option exercise | +49 | – | – | 8,752 |
| Sian Bigora Chief Development Officer | Jan 1, 2026 | Option exercise | +249 | – | – | 1,604 |
| Patrick Lin Chief Business - Strategy Off | Jan 1, 2026 | Option exercise | +193 | – | – | 1,753 |
| Wendy Guy Chief Administrative Officer | Apr 1, 2025 | Option exercise | +14,482 | – | – | 26,339 |
| David Young Pres. Research & Development, Director | Apr 1, 2025 | Option exercise | +17,272 | – | – | 222,677 |
| David Young Pres. Research & Development, Director | Apr 1, 2025 | Tax withholding | −5,345 | $0.41 | $2.19K | 217,332 |
| Patrick Lin Chief Business - Strategy Off | Apr 1, 2025 | Tax withholding | −4,814 | $0.41 | $1.97K | 38,727 |
| Patrick Lin Chief Business - Strategy Off | Apr 1, 2025 | Option exercise | +14,482 | – | – | 43,541 |
| Sian Bigora Chief Development Officer | Apr 1, 2025 | Option exercise | +15,059 | – | – | 36,937 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
0.94%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-43.8%
From 0M shares
Short volume, 20 days
42.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Processa Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,516 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?